OncologyOnline.net

Oncology Xagena

Search results for "Crizotinib"

In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene ( ALK ) have been associated with marked clinical responses to Crizotinib ( Xalkori ), an oral tyrosine kinas ...


Non–small-cell lung cancer ( NSCLC ) harboring the anaplastic lymphoma kinase gene ( ALK ) rearrangement is sensitive to the ALK inhibitor Crizotinib ( Xalkori ), but resistance invariably develops. ...


The efficacy of the ALK inhibitor, Crizotinib ( Xalkori ) as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non–small-cell lung cancer ( NSCLC ) is unknown. A ...


Results from two pivotal studies ( NP28673 and NP28761 ) have showen Alectinib, an oral investigational anaplastic lymphoma kinase inhibitor ( ALKi ), shrank tumours ( overall response rate; ORR: 50% ...


A Committee of the American Society of Clinical Oncology NSCLC Expert Panel carried out a systematic review of randomized controlled trials from January 2007 to February 2014 to provide evidence-base ...


A patient with metastatic BRAF-mutated colorectal cancer initially responded to combined EGFR and BRAF inhibition with Panitumumab plus Vemurafenib. Pre-existing cells with increased MET gene copy ...


Alectinib ( Alecensa ), an oral anaplastic lymphoma kinase ( ALK ) inhibitor, has reduced the risk of disease worsening or death ( progression free survival, PFS ) by 66% compared to Crizotinib ( Xalk ...